Insider · CIK 0001921163

Ali Asif

Reports to the SEC for 1 company · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001921163

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-30	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−28.4K sh	—	—	49,562
2026-09-30	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−9,229 sh	—	—	29,291
2026-09-30	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,229 sh	$38.98	+$360K	68,232
2026-09-30	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+28.4K sh	$23.42	+$666K	96,670
2026-09-30	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15.7K sh	$19.19	+$300K	112,320
2026-09-30	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,312 sh	$12.17	+$64.6K	117,632
2026-09-30	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−12.6K sh	$141.77	−$1.79M	105,037
2026-09-30	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−46K sh	$141.78	−$6.53M	59,003
2026-09-30	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,312 sh	—	—	25,235
2026-09-30	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15.7K sh	—	—	51,150
2026-04-20	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−1,750 sh	$105.47	−$185K	59,003
2026-03-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,265 sh	$12.17	+$64.1K	85,518
2026-03-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,265 sh	—	—	13,282
2026-03-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−19.5K sh	—	—	31,300
2026-03-26	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−24.8K sh	$104.24	−$2.58M	60,753
2026-03-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+19.5K sh	$19.19	+$374K	80,253
2026-01-27	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−28K sh	$83.13	−$2.33M	78,523
2026-01-27	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−16K sh	—	—	50,800
2026-01-27	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12K sh	—	—	18,547
2026-01-27	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−18.2K sh	$83.14	−$1.51M	60,320
2026-01-27	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+16K sh	$19.19	+$307K	94,523
2026-01-27	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12K sh	$12.17	+$146K	106,523
2026-01-20	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−8,588 sh	$82.48	−$708K	78,077
2026-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Financial Officer	AAward	+25.6K sh	—	—	86,665
2026-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+32K sh	—	—	32,000
2025-04-22	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−1,756 sh	$46.00	−$80.8K	61,065
2025-03-12	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−24.9K sh	$58.73	−$1.46M	62,821
2025-03-12	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−15.2K sh	—	—	30,547
2025-03-12	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−9,700 sh	—	—	66,800
2025-03-12	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+9,700 sh	$19.19	+$186K	87,724
2025-03-12	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+15.2K sh	$12.17	+$185K	78,024
2025-01-16	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−1,317 sh	—	—	65,422
2025-01-16	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−2,601 sh	—	—	62,821
2025-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Financial Officer	AAward	+31.8K sh	—	—	66,739
2025-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+38.5K sh	—	—	38,520
2024-09-11	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−2,203 sh	$44.59	−$98.2K	34,960
2024-09-11	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,000 sh	—	—	45,750
2024-09-11	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,000 sh	—	—	76,500
2024-09-11	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−12K sh	$44.47	−$534K	34,960
2024-09-11	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,000 sh	$12.17	+$73K	46,960
2024-09-11	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,000 sh	$19.19	+$115K	40,960
2024-04-18	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−1,234 sh	$25.11	−$31K	37,163
2024-03-01	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+12K sh	$12.17	+$146K	52,645
2024-03-01	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−12K sh	—	—	51,750
2024-03-01	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−2,248 sh	$32.33	−$72.7K	38,397
2024-03-01	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−12K sh	$32.22	−$387K	40,645
2024-02-29	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−7,850 sh	$30.61	−$240K	42,734
2024-02-29	PTGXProtagonist Therapeutics, IncS Sale	Chief Financial Officer	SSale	−2,089 sh	$31.00	−$64.8K	40,645
2024-01-16	PTGXProtagonist Therapeutics, IncF Tax Payment	Chief Financial Officer	FTax Payment	−1,452 sh	$24.63	−$35.8K	50,584
2024-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Financial Officer	AAward	+21K sh	—	—	52,036

Recent filings

Accepted (ET)
Oct 24
Ali Asif0001104659-26-113279
SEC(opens sec.gov)
Apr 214
Ali Asif0001104659-26-046110
SEC(opens sec.gov)
Mar 274
Ali Asif0001104659-26-036317
SEC(opens sec.gov)
Jan 274
Ali Asif0001104659-26-007128
SEC(opens sec.gov)

Companies

Protagonist Therapeutics, IncChief Financial OfficerPTGX

Address

C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560-1160